Gastrointestinal drugs market to hit $48.4 billion by 2022 as biologic products revolutionize the treatment space
Although the market has recently been hit by the patent expirations of a number of the leading gastrointestinal products, the approval of new drugs, as well as rising prevalence, are expected to drive considerable growth. says GBI Research.
The market size for gastrointestinal therapeutics is set to grow from $35.7 billion in 2015 to $48.4 billion by 2022, representing a compound annual growth rate of 4.45%, according to business intelligence provider GBI Research.
The company’s latest report states that although the market has recently been hit by the patent expirations of a number of the leading gastrointestinal products, such as Nexium and Remicade, the approval of new drugs, as well as rising prevalence, are expected to drive considerable growth.
Jennifer Goossens, Associate Analyst for GBI Research, explains: “Recently approved products include Intercept’s Ocaliva, for the treatment of primary biliary cirrhosis, and Takeda’s Takecab for acid-related diseases such as gastroesophageal reflux disease – which are both forecast to generate annual revenue of over $1 billion by 2022 – as well as Entyvio for inflammatory bowel disease (IBD).”
In terms of the gastrointestinal pipeline, there are 937 products in active development, most of which are small molecules and biologics. The therapy area is highly active and has the seventh-largest pipeline across the pharma industry, with more active pipeline products than therapy areas such as respiratory, ophthalmology, and dermatology.
Goossens continues: “The large portion of biologics in the early- and late-stage pipeline reflects the growing interest in biologic therapy in the treatment of gastrointestinal disorders. Currently, marketed biologics, including the monoclonal antibodies (mAbs) Humira and Remicade, only have an established market presence for the treatment of IBD.
“Due to the high costs and adverse effects, biologic treatment is primarily used in patients with refractory IBD, but this may change once newer products with a more favorable safety profile enter the market.
“Biologics have revolutionized IBD treatment, and their success in the treatment of these indications has driven enthusiasm for the use of biologics in other immune-related gastrointestinal conditions, such as celiac disease, eosinophilic esophagitis and autoimmune hepatitis. Of the 329 biologics in the pipeline, 87 products are being developed for ulcerative colitis and Crohn’s disease, while 226 are in development for other gastrointestinal indications.”
Biologics in clinical development include the mAbs Stelara (ustekinumab) for Crohn's disease and ulcerative colitis, AMG-714 for celiac disease, and dupilumab for eosinophilic esophagitis, and the recombinant protein BMS-9860 for nonalcoholic steatohepatitis.
In terms of top companies within the treatment space, Takeda is expected to take the title of market leader from AbbVie by the end of the forecast period. Johnson & Johnson, Allergan and AstraZeneca also remain key players in the gastrointestinal market, although AstraZeneca is forecast to lose a considerable portion of market share.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance